Skip to content
Home - Partnering - Key areas of partnering interest    
AstraZeneca in China

AstraZeneca recognises the rapid development of science and innovation in China related to discovery research and drug
development.

We are actively seeking strategic alliance opportunities and R&D collaborations with Chinese academia as well as pharmaceutical and biotechnology companies.

Key areas of partnering interest

• CNS, pain, oncology, respiratory, inflammation, diabetes, obesity, atherosclerosis, serious bacterial and fungal
infection, and special viral infections (e.g. RSV, HBV, HCV)
• Chemistry, protein biochemistry, predictive toxicology and
other skill and technology areas relevant for pharmaceutical R&D
• Late stage or in-market products from companies that are under-leveraged in China

Contacts
Jie Liu D’Elia -AstraZeneca China, Business Development
Richard Wang -  AstraZeneca Innovation Centre China

E-mail:
firstname.lastname@astrazeneca.com
- Replace with authentic names

AstraZeneca websites
Search